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Pre-eclampsia is a hypertensive disorder of pregnancy initiated by placental insufficiency
and chronic ischemia. In response, several pathways activated in the placenta are
responsible for the maternal syndrome, including increased production of the anti-
angiogenic protein, sFlt-1, and inflammatory cytokines, especially tumor necrosis factor-
alpha (TNF-a). Previous studies have demonstrated that heme oxygenase (HO) induction
can block TNF-a pathways in vitro and attenuate placental ischemia-induced sFlt-1 in
vivo. Here, we investigated whether HO-1 induction could attenuate TNF-a-induced
hypertension in pregnant rats. In response to TNF-a infusion (100 ng/day i.p.), maternal
mean arterial pressure (MAP) increased vs. control animals (104  3 vs. 119  3 mmHg).
HO-1 induction had no effect in control animals, but significantly decreased MAP in TNF-
a-infused animals (108  2 mmHg). Placental vascular endothelial growth factor (VEGF)
was decreased in response to TNF-a infusion (92 4 vs. 76 2 pg/mg). Placental sFlt-1
was increased by TNF-a infusion (758 45 vs. 936 46 pg/mg, p< 0.05), which trended
to normalization by HO-1 induction (779  98 pg/mg). In contrast, HO-1 induction had
no significant effect on placental VEGF in TNF-a-infused animals. Taken together, these
data suggest that one of the key mechanisms by which HO exerts cytoprotective actions
in the placenta during inflammation due to chronic ischemia is through suppression of
sFlt-1. Further work elucidating the bioactive metabolites of HO-1 in innate inflammatory
responses to placental ischemia is warranted.
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Introduction
Perhaps the most persistent and pervasive of obstetrical disorders is pre-eclampsia, which occurs in
approximately 5% of all births in the United States, is a contributor to up to 15% of all preterm births,
and is a leading cause of maternal/fetal morbidity (Meis et al., 1998; Sibai et al., 2005; American
College of Obstetricians and Gynecologists and Task Force on Hypertension in Pregnancy, 2013).
The classical definition of pre-eclampsia is new-onset hypertension during gestation with protei-
nuria; however, newer guidelines from the American Congress of Obstetricians and Gynecologists
suggest criteria of hypertension coupled with either proteinuria or a broader array of symptoms
(thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, or cerebral
and visual symptoms) could increase the diagnosis of this disorder in the population (American
College of Obstetricians and Gynecologists and Task Force on Hypertension in Pregnancy, 2013).
Despite intensive research, the underlying causes of pre-eclampsia remain obscure. However, it is
believed in most cases, especially the most severe, the underlying pathology is due to placental
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underperfusion. It is further believed that this is due to the
maternal spiral arteries, which feed the placenta to fully remodel
and vasodilate, and provide proper blood flow to the developing
uteroplacental unit. In response, the placenta becomes hypoxic
and ischemic, and begins to release soluble factors that are released
into the maternal bloodstream and cause the maternal symptoms
of the disorder (Lim et al., 1997; George and Granger, 2012).
The identities of these soluble factors have been a major
area of investigation, and several have been repeatedly and
strongly implicated in both patients and animal models of
placental ischemia, including the anti-angiogenic protein, sFlt-1,
and circulating autoantibodies to the angiotensin type 1 receptor
(Maynard et al., 2003; Xia et al., 2003). One of the earliest and
most consistent findings, however, is the activation of the innate
immune response, in particular inflammatory cytokines, such
as tumor necrosis factor-alpha (TNF-a) and IL-6 (Vince et al.,
1995). This increase in TNF-a and IL-6 has also been observed
in animal models of experimental placental ischemia (Gadonski
et al., 2006; LaMarca et al., 2008). Infusion of these factors
individually during pregnancy in rodents have been shown to
induce hypertension, though not to the degree seen in a placental
ischemic model, suggesting that they are only partially causative
of the phenotype (Alexander et al., 2002; Gadonski et al., 2006).
There has been some interest in targeting the TNF-a system as
a potential therapeutic approach for the management of pre-
eclampsia. There are unanswered questions as to the safety of
currently-used recombinant protein and antibody-based TNF-a
antagonists despite several ongoing trials assessing their safety
during pregnancy (George, 2014).
Several lines of evidence suggest that the detrimental
cardiovascular effects of TNF-a elevation could be attenuated
by induction of heme oxygenase-1 (HO-1). The predominant
function of HO is in the conversion of free heme from heme-
containing proteins to biliverdin, which is quickly converted by
biliverdin reductase to bilirubin, which can then be conjugated
for excretion in the bile. In the process, the biologically-active
byproducts, carbon monoxide (CO) and bilirubin, are produced.
These in turn are believed to have important roles in blood
pressure regulation through anti-inflammatory, antioxidant, and
vasorelaxation mechanisms (Cao et al., 2009). HO-1 induction
has been shown to be protective and anti-hypertensive in several
experimental models of hypertension, including the reduced
uterine perfusion pressure (RUPP)model, known to be associated
with elevated TNF-a levels (Sabaawy et al., 2001; Yang et al., 2004;
Botros et al., 2005; George et al., 2011b). Early reports suggested
that placental HO-1 induction could also protect the placenta
from TNF-a-induced cytotoxicity, perhaps preserving placental
function (Ahmed et al., 2000). Here, we test the hypothesis that
HO-1 induction can attenuate the hypertension associated with
elevated circulating TNF-a, and then determined the effects of
both on pro- and anti-angiogenic proteins in pregnant rats.
Materials and Methods
Animals
Timed pregnant Sprague Dawley rats (Harlan, Indianapolis, IN,
USA) were received on gestational day 11, held at a constant
23°C, and put on a 12:12-h light-dark cycle with food and
water ad libitum. All protocols were approved by the University
of Mississippi Medical Center Institutional Animal Care and
Use Committee and followed the National Institutes of Health
Guidelines for the Care and Use of Laboratory Animals.
TNF-a Administration and HO-1 Induction
On gestational day 14, animals in the experimental groups
were implanted i.p. with mini-osmotic pumps containing
recombinantly-expressed TNF-a (R&D Systems, Minneapolis,
MN, USA) or vehicle alone. TNF-a was received lyophilized and
reconstituted in sterile PBS. Mini-pumps (Model 2001, Alzet,
Cupertino, CA, USA) delivered TNF-a at a constant dose of
100 ng/day. Briefly, rats were anesthetized and maintained with
3% isoflurane. A ventral midline incision 3 cm in length was
made, and pumps were placed i.p. The incision was closed with
non-absorbable continuous sutures. Animals were euthanized
on gestational day 19 and tissues harvested post-mortem. For
HO-1 induction, on gestational day 14, cobalt protoporphyrin
IX chloride (CoPP, Frontier Scientific, Logan, UT, USA) was
injected i.p. at a dose of 5 mg/kg, which we have previously shown
to cause persistent elevation in HO-1 production in the placenta
(George et al., 2011a,b). Each experimental group consists of 7–8
animals.
Measurement of Arterial Pressure
On gestational day 18, animals were anesthetized as above,
and implanted with indwelling carotid catheters. The catheter
was externalized at the nape of the neck s.c.. The following
day, animals were placed in restraint cages and acclimatized.
Mean pressure was determined over the course of 30 min via
direct pressure transducers (ADInstruments, Bella Vista, NSW,
Australia).
Tissue Harvest
Rats were anesthetized as above. The uterus was externalized
thorough a ventral midline incision, and blood was collected by
cannulation of the abdominal aorta for isolation of plasma and
serum. Recordsweremade of the viable and resorbed pups present
in each animal, and individual pups and placentas were weighed
and recorded. Representative placental samples from each horn,
thoracic aortae, and livers were flash frozen in liquid nitrogen and
stored at 80°C for later analysis.
Measurement of sFlt-1, VEGF, and TNF-a
Placental protein was prepared from a representative placenta
from individual rats. Briefly, the frozen tissue was mechanical
ground by mortar and pestle in liquid nitrogen. Tissue fragments
were resuspended in radioimmunoassay buffer with protease
inhibitor cocktail, phenylmethanesulfonyl fluoride (PMSF), and
sodium orthovanadate (Santa Cruz Biotechnology Inc., Dallas,
TX, USA). Homogenization was performed via automated tissue
processor (MP Biomedicals, LLC, Santa Ana, CA, USA) and
the solution was cleared by centrifugation at 12000  g for
20 min. Resulting protein concentrations were measured by the
bicinchoninic acid method (Pierce Biotechnology, Rockford, IL,
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USA). Vascular endothelial growth factor (VEGF) and sFlt-1
were both measured using sandwich ELISA (R&D Systems, Inc.,
Minneapolis, MN, USA) in duplicate according to manufacturer’s
instructions.Measurements of free plasmaVEGFwere performed
with the same kit. Plasma TNF-a levels were measured using
a commercial ELISA per manufacturer’s instructions (R&D
Systems, Inc.).
Statistical Analyses
All date are displayed as means  SEM. Comparisons between
groupswere performed by one-wayANOVAwithTukey’smultiple
comparisons test at a significance threshold value of p < 0.05. All
statistical comparisons and graphs were generated with Prism 6
(GraphPad, La Jolla, CA, USA).
HO Activity Assays
Determination of total HO activity (n = 5 in each group)
in liver and placenta was performed as described previously
(Vera et al., 2007). Briefly, for HO activity, tissue lysates were
prepared and measured as above. Reactions were performed
in 1.2 mls consisting of: 2 mM glucose-6-phosphate, 0.2 units
glucose-6-phosphatedehydrogenase, 0.8 mM NADP, 20 mM
hemin, and 0.5 mg of protein from lysates. Incubations were
allowed to proceed for 1 h at 37°C. Resulting bilirubin was
chloroform extracted and concentration was determined by
change in optical density at 464–530 nm, utilizing an extinction
coefficient of 40mM/cm. Activity was expressed as pmol bilirubin
formed/hr/mg of protein. Five samples were analyzed in each
group.
Results
Chronic TNF-a Infusion Leads to Increased
Circulating Levels of TNF-a
To determine whether the administered dose of TNF-a was
sufficient to exert a biological effect, plasma levels of the
protein were determined via sandwich ELISA. Control animals
exhibited low circulating levels of TNF-a (Figure 1A; 3.8  0.2
pg/mL). Animals receiving TNF-a demonstrated a significant
50% increase in circulating TNF-a levels (6.1  0.9 pg/mL,
p < 0.05). Administration of CoPP had no significant effect on
the circulating levels of TNF-a in either control (2.8 0.4 pg/mL)
or TNF-a-infused rats (8.4  2.3 pg/mL). Taken together, these
data demonstrate that TNF-a infusion increases circulating levels
of TNF-a, while CoPP administration has no direct effect. The
efficacy of CoPP for induction of HO activity was ascertained by
examining HO activity in the livers and placentas of all groups. As
seen in Figures 1B,C, TNF alone had no effect onHO activity, but
increased HO activity in both control and TNF-infused animals.
HO-1 Induction Attenuates TNF-a-induced
Increases in Blood Pressure Without Adverse
Effects on Gross Fetal and Placental
Development
After 5 days of continuous infusion of TNF-a (Figure 2A),
pregnant dams exhibited a significant 15-mmHg increase (104 3
C
B
A
FIGURE 1 | Circulating plasma TNF-a levels were determined by ELISA
(A). In response to continuous i.p. TNF-a infusion (TNF), plasma levels were
elevated in both normal pregnant (NP) and CoPP-treated animals. There was
no statistical difference in circulating TNF-a levels between control or
CoPP-treated animals. Statistical significance at p < 0.05 is indicated by
connecting lines. (B) Liver and placenta (C) heme oxygenase activity was
determined in response to TNF-a infusion and CoPP administration. TNF-a
infusion alone had no effect on heme oxygenase activity, however, CoPP
administration significantly increased HO activity in both control and TNF-a
infused animals. Level of significance is indicated by asterisks (*p < 0.05,
**p < 0.005).
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FIGURE 2 | (A) In response to TNF-a infusion, mean arterial pressure was
significantly elevated compared to normal pregnant controls. Administration of
CoPP had no significant effect on mean pressure in normal pregnant animals,
but significantly reduced the mean pressure in animals infused with TNF-a.
There was no significant effect of either TNF-a infusion or CoPP treatment on
either fetal weight (B) or placental mass (C). Statistical significance at
p < 0.05 is indicated by connecting lines. Level of significance is indicated by
asterisks (*p < 0.05, **p < 0.005).
vs. 119  3 mmHg, p < 0.005) in mean arterial pressure
(MAP). While administration of the HO-1 inducer CoPP had
no effect on control animals (104  3 vs. 105  3 mmHg),
it significantly attenuated the rise in blood pressure caused by
infusion of TNF-a (119  3 vs. 108  2 mmHg, p < 0.05).
These data suggest that induction of HO-1 has no effect on
blood pressure under normal conditions in pregnant rats, but
blocks the hypertensive effects of TNF-a during pregnancy. In
line with other published data in pregnant rodents, there was
no effect of HO-1 induction on either fetal or placental mass
(Figures 2B,C).
HO-1 Induction Has Differential Effects on
Placental VEGF and sFlt-1 Levels
To determine the effects of TNF-a infusion and HO-1 induction
on the pro-angiogenic protein VEGF and its antagonist sFlt-1,
placental levels of both were determined by sandwich ELISA.
Interestingly TNF-a infusion resulted in a decrease in placental
VEGF (92  4 vs. 76  2 pg/mg, p < 0.05; Figure 3A), and
an increase in placental sFlt-1 (758  45 vs. 936  46 pg/mg,
p < 0.05; Figure 3B). In control animals, while HO-1 induction
had no significant effect on placental sFlt-1 (Figure 3B); there
was significant, decrease in placental VEGF (93  4 vs. 73  7
pg/mg, p < 0.05; Figure 3A). Induction of HO-1 in TNF-a-
infused animals likewise had no effect on placental VEGF. There
was, however, a strong trend toward normalization of placental
sFlt-1 levels, but was not statistically significant (936  46 vs.
779  98 pg/mg, p= 0.09).
Discussion
Despite intensive research into the central causes and molecular
mechanisms responsible for the maternal pathology of pre-
eclampsia, little in the way of new therapeutic approaches
has been translated into the clinical setting. It is now widely
believed that defects in placental development, specifically failure
to adequately remodel the maternal vasculature feeding the
placenta, are a key central mechanism in the development of
the disorder (Lim et al., 1997; George and Granger, 2012). In
response, several key pathways activated in response to placental
ischemia have been identified in the maternal symptomatic
response; key among them being angiogenic imbalance, innate
immune activation, production of oxidative stress, and adaptive
immune responses. HO and its metabolic byproducts have been
shown to affect several of these pathways independently. HO,
CO, and bilirubin have all been shown to down-regulate sFlt-
1 production both in vivo and in vitro (Cudmore et al., 2007;
George et al., 2011b, 2012). Bilirubin is a potent antioxidant, which
demonstrates a beneficial effect in hypoxia-induced superoxide
production, and has been shown to attenuate angiotensin II-
induced hypertension experimentally (Vera and Stec, 2010;
George et al., 2012; Stec et al., 2013). Recently, we have
utilized two models of experimental hypertension in rodents
to determine the beneficial effects of HO-1 induction. In the
first, we use the RUPP rodent model, which induces placental
ischemia in late gestation and shares many features of severe
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FIGURE 3 | Infusion of TNF-a led to a small, but significant, decrease
in placental VEGF (A), as did administration of CoPP. There was no
statistically significant difference between TNF-a-infused animals with or
without CoPP administration. TNF-a infusion was associated with an increase
in placental sFlt-1 (B). CoPP had no effect on placental sFlt-1 in normal
pregnant animals, but trended to normalization of sFlt-1 levels in
TNF-a-infused animals, though this failed to meet significance (p = 0.09).
Statistical significance at p < 0.05 is indicated by connecting lines. Level of
significance is indicated by asterisks (*p < 0.05).
pre-eclampsia. Induction of HO-1 in these animals not only
attenuated the hypertension, but also normalized angiogenic
balance and placental superoxide production (George et al.,
2011b). In the second model, we used the sFlt-1 infusion
model, which clamps circulating sFlt-1 at an elevated level. Here
too, hypertension was attenuated, which suggests HO-1 activity
independent of sFlt-1 suppression (George et al., 2011a). One
pathway known to be activated in response to placental ischemia
(in which HO-1 induction has not been adequately described
in vivo) is the induction of inflammatory cytokines—TNF-a in
particular.
Elevation of TNF-a has been one of the most consistent
findings in both pre-eclamptic patients and experimental forms
of placental ischemia-induced pre-eclampsiamodels (Kupferminc
et al., 1994; Vince et al., 1995; LaMarca et al., 2008). Previously, it
has been reported that infusion of TNF-a to pregnant rodents to
roughly equivalent levels seen in pre-eclamptic patients results in
hypertension, though the degree of hypertension displayed is not
equivalent to that seen in placental ischemia models (Alexander
et al., 2002; LaMarca et al., 2005; Gadonski et al., 2006).
Importantly, though antagonism of TNF-a by administration of
a soluble receptor tended to decrease the hypertension associated
with placental ischemia, this was not significant, suggesting that
its hypertensive effects are only a part of a much broader response
(LaMarca et al., 2008).
Several previous reports have supported a potential
cytoprotective effect of HO-1 in response to TNF-a exposure.
Using placental tissue explants, Ahmed et al. (2000) first
demonstrated that HO-1 induction, via hemin exposure, was
capable of protecting cells from TNF-a-induced cytotoxicity.
More recently, Pullikotil et al. (2012) suggested that induction of
HO-1 was the mechanism by which epigallocatechin suppressed
the inflammatory activity of TNF-a in vascular endothelial cells.
Finally, Ndisang recently demonstrated that induction of HO-1
in the spontaneously-hypertensive rat resulted in significantly
lower levels of a number of inflammatory cytokines, including
TNF-a and IL-6 (Ndisang, 2014). While TNF-a has been shown
to stimulate placental sFlt-1 expression, there are no reports on
whether induction of HO-1 attenuates TNF-a-induced sFlt-1
production.
Here, we have attempted to examine directly the effects of HO-
1 induction in a TNF-a infusionmodel of hypertension in rodents
during late gestation. As a consequence of TNF-a infusion,
circulating levels of the cytokine were elevated approximately
50% compared to controls. These levels were not affected by the
induction of HO-1 by CoPP in either control or TNF-a groups.
Consistent with previously published reports in pregnant rodent
models, infusion of TNF-a resulted in a significant increase in
blood pressure of 15 mmHg. Induction of HO by CoPP was
measured by enzymatic activity in both liver and placenta, and
was found to be elevated in both tissues in both control and
TNF-a infused animals at similar levels. HO induction, which
had no effect on blood pressure in control animals, returned
blood pressure to levels undistinguishable from controls in TNF-
a animals. Promisingly, this had no significant detrimental effects
on either placental or fetal weight, suggesting thatHO-1 induction
had no negative effect on placental efficiency. Interestingly, TNF-
a infusion was associated with increased placental levels of sFlt-1
and decreased levels of VEGF. In both cases, induction of HO-1
caused trends to normalization of both proteins, though neither
reached statistical significance. Together, these data suggest that,
among other potential pathways, one of themechanisms by which
HO-1 induction could be attenuating the effects of TNF-a in
response to placental ischemia is through modulation of sFlt-1
and/or VEGF.
Still unknown is the underlying molecular mechanism by
which HO-1 is eliciting this effect. As it has been previously
reported that CO suppresses sFlt-1, it is possible that this is the
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bioactive component at work here (Cudmore et al., 2007; George
et al., 2012). Whether the signaling of the CO, the antioxidant
effects of bilirubin, or other undetermined effects are responsible
are still open fields for investigation. Further work examining
the contributions of the individual metabolites to this therapeutic
effect should prove enlightening.
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